L-NG-monomethyl Arginine (L-NMMA)
Phase 1Small molecule
L-NG-monomethyl Arginine (L-NMMA) is one of 11 small molecule programs targeting Vasovagal syncope. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Vasovagal Syncope
#DrugCompanyPhaseTrials
1Vivarin
HHikma Pharmaceuticals LLC
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Midodrine Hydrochloride
TakedaPhase 3
Zofran
NovartisPhase 2
Fludrocortisone Acetate
Merck & Co.Phase 3
Atomoxetine /kg/day
Eli LillyPhase 3
Strattera
MMap77
Phase 2
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 1
Proamatine
TakedaPreclinical
Northera
NNew York Medical College
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Endothelial Function1 trial
Endothelial Function in Lower Extremity Bypass Grafts
Completed·—·N/A·NCT00759707·19 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEmory University